Core Viewpoint - Despite goodwill impairment in subsidiaries due to industry conditions, the company is committed to advancing its diversification strategy, effectively mitigating concentration risks and opening broader market opportunities for future growth [2][9]. Financial Performance - The company forecasts revenue of 5.5 billion to 6 billion yuan for 2025, with a projected net profit attributable to shareholders of -250 million to -300 million yuan [2][9]. - The chain pharmacy sector is expected to experience a temporary decline in performance due to macroeconomic changes, intensified competition, policy adjustments, and shifts in consumer habits [2][9]. Professional Pharmacy Advantages - The company has established a solid operational management system and high pharmaceutical service capabilities over its 20 years in the professional pharmacy sector [3][10]. - As a national 4A-level pharmaceutical logistics enterprise, the company enhances its retail business through effective logistics and supply chain management [3][10]. - The company operates 1,505 pharmacies nationwide, covering multiple provinces and cities, and continues to expand its network through a "direct + acquisition + franchise" model [3][10]. Diversification Strategy - The company is deepening industry chain cooperation and plans to diversify its pharmacy offerings, focusing on health food and personal care products to create patient-centered "health service hubs" [4][11]. - The company is actively pursuing diversification in the health industry, achieving progress in pharmaceutical manufacturing and regenerative medicine [5][12]. Regenerative Medicine Initiatives - In 2025, the company will collaborate with several institutions to establish a clinical research center for regenerative medicine, aiming to translate research outcomes into clinical applications and accelerate the development of Hunan's biopharmaceutical industry [5][12]. - The establishment of the center is supported by a 1 billion yuan special fund from Hunan Province to facilitate technology transfer and research breakthroughs [5][12]. Pharmaceutical Manufacturing - The company owns two pharmaceutical enterprises with a total of 63 drug approvals and 21 drug registration certificates, with 46 products included in the national medical insurance directory [6][13]. - The company is focusing on the development of innovative drugs, including original chemical drugs and traditional Chinese medicine, and has established key laboratories and technology centers [6][13]. Hospital Sector Developments - The company’s hospital, Dajia Jiacheng Hospital, has entered the medical beauty sector, which is expected to improve operational performance [6][13]. - The hospital has launched various beauty treatment projects and is poised to benefit from upcoming policies that relax market access for high-end medical services [6][13]. Strategic Goals - The company aims to strengthen its core competitiveness and profitability by enhancing management practices, talent development, and leveraging existing business synergies to seize opportunities in the healthcare industry [7][14].
发力多元化，达嘉维康预计2025年营收超过55亿元